Positive phase 1 clinical data of mtx110 in dmg brain cancer demonstrating increased survival presented at ispno 2024

July 2, 2024 biodexa pharmaceuticals plc positive phase 1 clinical data of mtx110 in dmg brain cancer demonstrating increased survival presented at ispno 2024 after only two infusions and two patients at optimal dose, median overall survival across all patients was 16.5 months (vs 10.0 months in historical reference cohort) (dateline) july 2 -- biodexa pharmaceuticals plc (“biodexa” or the “company”) (nasdaq: bdrx), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces data from a phase 1 study of mtx110 in diffuse midline glioma (“dmg”) f/k/a diffuse intrinsic pontine glioma, or dipg, an orphan pediatric brain cancer were presented over the weekend at the 21st international symposium on pediatric neuro-oncology (ispno 2024) in philadelphia, pa. results of the phase 1 study overall, the treatment was well tolerated by patients.
BDRX Ratings Summary
BDRX Quant Ranking